Geron Corporation  

(Public, NASDAQ:GERN)   Watch this stock  
Find more results for GERN
3.83
-0.01 (-0.13%)
Real-time:   11:34AM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 3.80 - 3.89
52 week 1.76 - 4.49
Open 3.84
Vol / Avg. 395,497.00/2.39M
Mkt cap 605.48M
P/E     -
Div/yield     -
EPS -0.23
Shares 158.09M
Beta 2.07
Inst. own 44%
Aug 10, 2015
Q2 2015 Geron Corp Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
May 20, 2015
Geron Corp Annual Shareholders Meeting (Estimated)
May 18, 2015
Geron Corp Annual Shareholders Meeting - Webcast
May 13, 2015
Geron Corp at Bank of America Merrill Lynch Health Care Conference
Apr 30, 2015
Q1 2015 Geron Corp Earnings Release
Apr 14, 2015
Geron Corp at Needham Healthcare Conference
Mar 3, 2015
Q4 & FY 2014 Geron Corp Earnings Call - Webcast
Mar 3, 2015
Q4 & FY 2014 Geron Corp Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -1734.64% -3093.67%
Operating margin -1760.89% -3149.35%
EBITD margin - -3145.27%
Return on average assets -22.09% -29.74%
Return on average equity -29.20% -37.45%
Employees 42 -
CDP Score - -

Address

SUITE 2070, 149 COMMONWEALTH DRIVE
MENLO PARK, CA 94025
United States - Map
+1-650-4737700 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Geron Corporation (Geron) is a clinical-stage biopharmaceutical company developing a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. Telomerase is an enzyme that enables cancer cells to maintain telomere length, which provides them with the capacity for limitless cellular replication. Imetelstat is a specific inhibitor of telomerase. The Company operates in one segment, the discovery and development of therapeutic products for oncology. Geron focuses to develop imetelstat to treat one or more hematologic myeloid malignancies, such as myelofibrosis (MF), myelodysplastic syndromes (MDS), or acute myelogenous leukemia (AML). The Company generates its revenues from research support payments under collaboration agreements and milestones, royalties and other revenues from its licensing arrangements.

Officers and directors

Hoyoung Huh Ph.D Independent Chairman of the Board
Age: 46
Bio & Compensation  - Reuters
John A. Scarlett M.D. President, Chief Executive Officer, Director
Age: 64
Bio & Compensation  - Reuters
Olivia K. Bloom Chief Financial Officer, Executive Vice President - Finance, Treasurer
Age: 46
Bio & Compensation  - Reuters
Stephen N. Rosenfield J.D. Executive Vice President, General Counsel and Corporate Secretary
Age: 65
Bio & Compensation  - Reuters
Andrew J. Grethlein Ph.D. Executive Vice President - Development and Technical Operations
Age: 50
Bio & Compensation  - Reuters
Melissa A. Kelly Behrs Executive Vice President - Business Development and Portfolio and Alliance Management
Age: 51
Bio & Compensation  - Reuters
Susan M. Molineaux Ph.D. Director
Age: 61
Bio & Compensation  - Reuters
Daniel M. Bradbury Independent Director
Age: 53
Bio & Compensation  - Reuters
Karin Eastham CPA Independent Director
Age: 65
Bio & Compensation  - Reuters
V. Bryan Lawlis Jr., Ph.D. Independent Director
Age: 63
Bio & Compensation  - Reuters